VEGFA and central nervous system cancer: Since the VEGF and PDGF pathways are critical in gliomas, they selected vandetanib, an inhibitor of both VEGFR-2 and EGFR [144] and dasatinib, an inhibitor of PDGFR [145] Twenty-five children (aged 18 months to 20 years) with newly diagnosed DIPG were enrolled to evaluate the safety, MTD, pharmacokinetics, and pharmacodynamics of this combination administered during and after radiotherapy.